Device Trial Radar · NCT02922088
EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]
Last checked: Nov 21, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,964
Actual
Start
Dec 9, 2016
Primary completion
Aug 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Somahlution LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 3, 2016
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DuraGraft® Registry is a European registry of patients who have undergone CABG and whose vascular grafts have been treated with DuraGraft. All participating sites will be from countries in Europe. The DuraGraft Registry will collect pre-CABG, intraoperative and post-operative data, major post-CABG cardiovascular adverse events, health economic outcomes and patient reported quality of life over a period of 5 years.
Conditions
- Cardiovascular Diseases
- Coronary Artery Disease
Interventions
DuraGraftDevice
DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Major Adverse Cardiac Events (MACE)Time frame: Annually up to 5 years post-CABG Surgery
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria
35 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.